Abstracts Archive - Page 1921 of 2607 - ACR Meeting Abstracts

Abstract Number: 748 • 2015 ACR/ARHP Annual Meeting
Comparison of Systemic Lupus Erythematosus in 3 Different Asian Ethnic Groups: Results from the 1000 Faces of Lupus Cohort
Mai Nguyen¹, Earl Silverman², Janet E. Pope³, Paul R. Fortin⁴, Ann E. Clarke⁵, Christian Pineau⁶, Sasha R Bernatsky⁷, C Douglas Smith⁸, Gaëlle Chédeville⁹, Lori B. Tucker¹⁰, Michel Zummer¹¹, Marie Hudson⁶, Adam M. Huber¹², Deborah M. Levy¹³, Hector Arbillaga¹⁴, Carol Hitchon¹⁵, Christine A. Peschken¹⁶ and CaNIOS 1000 Faces Investigators, ¹Medicine, University of Manitoba, Winnipeg, MB, Canada, ²Division of Rheumatology, Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, ³University of Western Ontario, London, ON, Canada, ⁴Medicine, CHU de Québec - Université Laval, Québec, QC, Canada, ⁵Immunology/Epidemiology, Montreal General Hospital, Montreal, QC, Canada, ⁶Medicine, McGill University, Montreal, QC, Canada, ⁷Division of Rheumatolog, McGill Unversity Health Cener, Montreal, QC, Canada, ⁸The Arthritis Centre, TOH Riverside Campus, Ottawa, ON, Canada, ⁹Rheumatology, McGill University, Montreal, QC, Canada, ¹⁰Rheumatology, BC Children's Hospital, Vancouver, BC, Canada, ¹¹Rheumatology, Hôpital Maisonneuve-Rosemont and University of Montreal, Montreal, QC, Canada, ¹²Pediatric rheumatology, IWK Health Centre, Halifax, NS, Canada, ¹³Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ¹⁴Calgary Rheumatology, Calgary, AB, Canada, ¹⁵University of Manitoba, Winnipeg, MB, Canada, ¹⁶Rheumatology, Univ of Manitoba, Winnipeg, MB, Canada
Background/Purpose: Ethnic variations in systemic lupus erythematosus (SLE) are well described, with more prevalent and severe disease in non-Caucasians including North American Asians. However, Asian…
Abstract Number: 749 • 2015 ACR/ARHP Annual Meeting
Microvesicles Containing Nucleic Acids and Expressing Immunoglobulins and HMGB1 Are Abundant in Patients with Systemic Lupus Erythematosus
Fariborz Mobarrez¹, Håkan Wallén², Iva Gunnarsson³, Johanna Gustafsson⁴, Agneta Zickert³, David Pisetsky^5,6 and Elisabet Svenungsson⁴, ¹Department of Medicine, Karolinska Institutet, Rheumatology Unit, Karolinska University Hospital, Stockholm, Sweden, ²Division of Cardiovascular Medicine, Karolinska Institutet, Department of Clinical Sciences, Stockholm, Sweden, ³Department of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, ⁴Department of Medicine, Karolinska Insitutet, Rheumatology Unit, Karolinska University Hospital, Stockholm, Sweden, ⁵Medical Research Service, Durham VA Hospital, Durham, NC, ⁶Department of Medicine, Duke University Medical Center,, Durham, NC
Background/Purpose: Systemic lupus erythematosus (SLE) is a prototypic autoimmune disease characterized by immune complexes of antinuclear antibodies. As a source of these antigens, increased levels…
Abstract Number: 750 • 2015 ACR/ARHP Annual Meeting
Belimumab for Systemic Lupus Erythematosus: A Cochrane Systematic Review and Meta-Analysis
Jasvinder A. Singh¹ and Nipam Shah², ¹University of Alabama at Birmingham, Birmingham, AL, ²University fo Alabama at Birmingham, Birmingham, AL
Background/Purpose: Belimumab is a new approved treatment option for patients with lupus. Our objective was to perform a systematic review of benefits and harms of…
Abstract Number: 751 • 2015 ACR/ARHP Annual Meeting
Rituximab Induced Serum Sickness: A Systematic Review
Paras Karmacharya¹, Dilli Poudel¹, Ranjan Pathak¹, Anthony Donato², Sushil Ghimire¹, Smith Giri³, Madan Aryal¹ and Clifton O. Bingham III⁴, ¹Internal Medicine, Reading Health System, WEST READING, PA, ²Internal medicine, Reading Health System, WEST READING, PA, ³Internal medicine, University of Tennessee Health Science Center, Memphis, TN, ⁴Rheumatology, Johns Hopkins University, Baltimore, MD
Background/Purpose: Rituximab (anti-CD20 monoclonal antibody) has been frequently used to treat various autoimmune diseases in which B-cells are participants, and for hematological malignancies in which…
Abstract Number: 752 • 2015 ACR/ARHP Annual Meeting
A Strong Association Between Gout and Diuretic Use Among Lupus Patients
Eric Wise¹, Emily Lewis², Puja Khanna^2,3, Lili Zhao⁴ and W Joseph McCune⁵, ¹Rhuematology, University of Michigan, Ann Arbor, MI, ²Rheumatology, University of Michigan, Ann Arbor, MI, ³Division of Rheumatology/Dept. of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI, ⁴Department of Statistic, University of Michigan, Ann Arbor, MI, ⁵Int Med/ Rheum, University of Michigan, Ann Arbor, MI
Background/Purpose: Although gout has historically been thought to be a rare in patients with SLE, recent case series suggest that the incidence of gout in…
Abstract Number: 753 • 2015 ACR/ARHP Annual Meeting
Serum Levels of Tenascin-C Discriminate Patients with Active SLE from Inactive Patients and Healthy Controls, and Predict the Need to Escalate Immunosuppressive Therapy
Jakub Zavada¹, Michal Uher², Radka Svobodova³, Marta Olejarova¹, Marketa Husakova³, Hana Ciferska³, Hana Hulejova⁴, Ladislav Senolt³ and Jiri Vencovsky³, ¹Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ²Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic, ³Institute of Rheumatology, Prague, Czech Republic, ⁴Institute of Rheumatology and Department of Rheumatology, Prague, Czech Republic
Background/Purpose: The aim of this study was to examine whether circulating levels of the pro-inflammatory glycoprotein tenascin-C (TSC) are useful as an activity-specific or predictive…
Abstract Number: 754 • 2015 ACR/ARHP Annual Meeting
Glutathione S Transferases (GST) Polymorphisms Are Independents Predictors of Efficacy and Toxicity in Lupus Nephritis Treated with Cyclophosphamide
Alexandra Audemard-Verger¹, Nicolas Martin Silva², Céline Verstuyft³, Nathalie Costedoat-Chalumeau⁴, Aurélie Hummel⁵, Véronique Le Guern⁴, Karim Sacre⁶, Olivier Meyer⁷, Eric Daugas⁸, Cecile Goujard⁹, Audrey Sultan², Thierry Lobbedez², Lionel Galicier¹⁰, Jacques Pourrat¹¹, Claire Le Hello², Michel Godin¹², Remy Morello², Marc Lambert¹³, Eric Hachulla¹³, Philippe Vanhille¹⁴, Guillaume Queffeulou¹⁵, Jacques Potier¹⁵, Jean Jacques Dion¹⁶, P Bataille¹⁷, Dominique Chauveau¹⁸, Guillaume Moulis¹⁹, Dominique Farge²⁰, Pierre Duhaut²¹, Bernadette Saint Marcoux²², Alban Deroux²³, Jennifer Manuzak²⁴, Camille Francès²⁵, Olivier Aumaître²⁶, Holy Bezanahary²⁷, Laurent Becquemont²⁸ and Boris Bienvenu²⁹, ¹Internal Medicine, CHU Caen, caen, France, ²CHU Caen, caen, France, ³Pharmacology, Hopital Bicêtre, Le Kremlin Bicêtre, France, ⁴Internal Medicine Department, Cochin Hospital, “René-Descartes Paris V” University, Paris, France, ⁵Necker, paris, France, ⁶Internal Medicine, Hospital Bichat, Paris, France, ⁷Rheumatology, Hopital Bichat, Paris, France, ⁸Internal Medicine, AP-HP Hôpital Bîchat, Paris, France, ⁹Bichat, Paris, France, ¹⁰Clinical Immunology, St Louis Hospital, Paris, France, ¹¹Nephrology, Rangeuil Hospital, Paris, France, ¹²CHU Rouen, Rouen, France, ¹³CHU Lille, Lille, France, ¹⁴Department of Nephrology and Internal Medicine, Hospital of Valenciennes, Valenciennes, France, Valenciennes, Valenciennes, France, ¹⁵Ch Cherbourg, Cherbourg, France, ¹⁶Ch Charleville Mezeiere, Charleville Mezeiere, France, ¹⁷Ch Boulogne sur Mer, Boulogne sur Mer, France, ¹⁸CH Toulouse, Toulouse, France, ¹⁹CHU Purpan, Toulouse, France, ²⁰Internal Medicine, Hopital St Louis, Paris, France, ²¹Department of Internal Medicine and RECIF, CHU Amiens, Amiens, France, ²²CH Aulnay sous Bois, Aulnay sous Bois, France, ²³Internal Medicine, CHU Grenoble, Grenoble, France, ²⁴Institut Cochin, Paris, France, ²⁵Dermatology Service, Tenon Hospital, Paris, France, ²⁶Department of Internal Medicine 2. Referal center for SLE/APS, CHU Pitié-Salpêtrière, Paris, France, ²⁷Internal Medicine, University Hospital of Limoges, Limoges, France, ²⁸KB, Paris, France, ²⁹Internal Medicine, Hospital Caen, Caen, France
Background/Purpose: Cyclophosphamide (CYC) is effective in inducing remission of lupus nephritis (LN). CYC, as a pro-drug, requires bioactivation through multiple hepatic cytochrome P450s and glutathione…
Abstract Number: 755 • 2015 ACR/ARHP Annual Meeting
Validating the RAIL Algorithm in Adult Lupus Nephritis Patients
Gaurav Gulati¹, Khalid Abulaban², Jun Ying³, Xiaolan Zhang⁴, Huijuan Song⁵, Qing Ma⁶, Christopher Haffner⁶, Kasha Wiley⁷, Michael Bennett⁸, Brad H. Rovin⁵ and Hermine I. Brunner⁹, ¹Division of Immunology, Allergy and Rheumatology, University of Cincinnati College of Medicine, Cincinnati, OH, ²Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³University of Cincinnati, Cincinnati, OH, ⁴Ohio State University, Columbus, OH, ⁵Ohio State University Medical Center, Columbus, OH, ⁶Cincinnati Children's Hospital and Medical Center, Cincinnati, OH, ⁷Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁸Division of Nephrology, Cincinnati Children`s Hospital Medical Center, Cincinnati, OH, ⁹Pediatric Rheumatology Collaborative Study Group, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Lupus Nephritis (LN) significantly contributes to morbidity and mortality among Systemic Lupus Erythematosus (SLE) patients. We have established the Renal Activity Index for Lupus…
Abstract Number: 756 • 2015 ACR/ARHP Annual Meeting
Axl, Ferritin, IGFBP2 and TNFR2 As Biomarkers in Systemic Lupus Erythematosus
Chi Chiu Mok¹, Huihua Ding², Marwa Kharboutli³ and Chandra Mohan², ¹Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong, ²Biomedical Engineering, University of Houston, Houston, TX, ³Department of Biomedical Engineering, University of Houston, Houston, TX
Background/Purpose: To evaluate the performance of 4 novel serum protein markers for detecting concurrent disease activity in systemic lupus erythematosus (SLE). Methods: Consecutive patients who…
Abstract Number: 757 • 2015 ACR/ARHP Annual Meeting
The Ratio Between TNF-a and P-Albumin – a Suggested Measure of Disease Activity in SLE
Susanna Eketjäll¹, Helena Idborg², Johanna Gustafsson³, Agneta Zickert², Marika Kvarnstrom⁴, Vilija Oke⁵, Susanne Pettersson⁴, Per Johan Jakobsson⁴, Iva Gunnarsson⁴ and Elisabet Svenungsson⁴, ¹Department of Clinical Neuroscience, Karolinska Institutet, Solna, AstraZeneca Translational Sciences Centre, Science for Life Laboratory, Personal Healthcare and Biomarkers, Stockholm, Sweden, ²Department of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, ³Department of Medicine, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ⁴Department of Medicine, Unit of Rheumatology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ⁵Department of medicine, Unit of Rheumatology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
Background/Purpose: There is presently no consensus on how to best measure disease activity in systemic lupus erythematosus (SLE). Available validated measures, such as SLE Disease…
Abstract Number: 758 • 2015 ACR/ARHP Annual Meeting
Dominican Patients with Systemic Lupus Erythematosus Residing in New York City Have a Higher SLICC/ACR Damage Index Than Those in the Dominican Republic
Laura Geraldino-Pardilla¹, Ivonne Canto², Thania Perez³, Jossiell Then², Esthela Loyo⁴ and Anca D. Askanase⁵, ¹Division of Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, ²Rheumatology, Hospital Regional Universitario Jose Maria Cabral y Baez, Santiago, Dominican Republic, ³Columbia University, College of Physicians & Surgeons, New York, NY, ⁴Rheumatology, Hospital Regional Universitario, Santiago, Dominican Republic, ⁵Department of Medicine Rhemuatology, Colombia University, New York, NY
Background/Purpose: Higher accrual of damage has been reported in Hispanics with systemic lupus erythematosus (SLE) in the United States. This study was initiated to evaluate…
Abstract Number: 759 • 2015 ACR/ARHP Annual Meeting
Prolactin Level Is Independently Associated with Circulating CD4+CD28null in Systemic Lupus Erythematosus Patients
Manuel Ugarte-Gil^1,2, César Sánchez-Zúñiga³, Rocio V. Gamboa-Cardenas¹, Madeley Aliaga-Zamudio³, Francisco Zevallos¹, Giannina Tineo-Pozo³, Jorge M. Cucho-Venegas¹, Ana Mosqueira-Riveros³, Risto Perich-Campos^1,4, Jose Alfaro-Lozano¹, Mariela Medina¹, Zoila Rodriguez-Bellido^1,4, Graciela S. Alarcon⁵ and Cesar A. Pastor-Asurza^1,4, ¹Rheumatology, Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, ²Universidad Cientifica del Sur, Lima, Peru, ³Molecular Biology, Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, ⁴Universidad Nacional Mayor de San Marcos, Lima, Peru, ⁵Medicine, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Peripheral CD4+CD28null T-cells are a subset of long-lived cytotoxic CD4+ T-cells with pro-inflammatory functions, and they are increased in autoimmune and cardiovascular diseases. Prolactin…
Abstract Number: 760 • 2015 ACR/ARHP Annual Meeting
Impact of Baseline Concomitant Medication Use on Belimumab Efficacy and Safety in Patients with Systemic Lupus Erythematosus (SLE)
Andreas Schwarting¹, Mary Anne Dooley², David Roth³, Lisa Edwards⁴, April Thompson⁴ and Barbara Wilson⁴, ¹ACURA Kliniken, Bad Kreuznach, Germany, ²University of North Carolina, Chapel Hill, NC, ³GlaxoSmithKline, King of Prussia, PA, ⁴GlaxoSmithKline, Chapel Hill, NC
Background/Purpose: Belimumab is licensed as add-on therapy to standard lupus care (SoC) in patients with active SLE. Physicians have inquired about the efficacy and safety…
Abstract Number: 761 • 2015 ACR/ARHP Annual Meeting
Neurometabolic Alterations in Korean Lupus Patients with Chronic Daily Headache
Ji-Min Kim¹, Tae-Han Lee¹, Chang-Nam Son¹, Sung Soo Kim², Hyuk Won Chang³ and Sang-Hyon Kim¹, ¹Division of Rheumatology, Department of Internal Medicine, Dongsan Medical Center, Keimyung University School of Medicine, Daegu, South Korea, ²Division of Rheumatology, Department of Internal Medicine, Ulsan University School of Medicine, GangNeung Asan Hospital, Gangneung, South Korea, ³Department of Radiology, Keimyung University School of Medicine, Daegu, South Korea
Background/Purpose: Neuropsychiatric systemic lupus erythematosus (SLE) includes a broad spectrum of neurologic and psychiatric manifestations. One of the most commonly observed neuopsychiatric symptoms is headache.…
Abstract Number: 762 • 2015 ACR/ARHP Annual Meeting
The Interferon Signature Correlates with Longitudinal Disease Severity in Systemic Lupus Erythematosus, but Adds Little to Conventional Prognostic Indicators
Arundip Asaduzzaman¹, Babak Noamani², Denisse Bonilla³, Dafna Gladman⁴, Murray Urowitz^5,6, Paul R. Fortin⁷, Carolina Landolt-Marticorena⁸ and Joan E. Wither⁹, ¹Rheumatology, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ²Genetics and developmental biology, University Health Network, Toronto, ON, Canada, ³University Health Network, Toronto, ON, Canada, ⁴Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁵University of Toronto, Toronto, ON, Canada, ⁶Rheumatology, U of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁷Université Laval, CHU de Québec, Québec, QC, Canada, ⁸1E420/Div of Rheumatology, University Health Network, Toronto, ON, Canada, ⁹Rheumatology, University Health Network, Toronto, ON, Canada
Background/Purpose: Type I interferon (IFN) is thought to play an important part in the pathophysiology of systemic lupus erythematosus (SLE), and cross-sectional data suggests an…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].